Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies
In This Article:
Sarepta stock plummeted Monday after the company said a second patient died following treatment with its gene therapy, Elevidys.
Oops, something went wrong
Sarepta stock plummeted Monday after the company said a second patient died following treatment with its gene therapy, Elevidys.